Literature DB >> 17414040

Tympanic membrane perforation among adults in West Africa.

Titus S Ibekwe1, G Taiwo A Ijaduola, Onyekwere G B Nwaorgu.   

Abstract

CONTEXT: The knowledge of variations of the tympanic membrane (TM) perforations with the climatic changes in the West African subregion would help clinicians in its prevention and management.
OBJECTIVE: To analyze the pattern of clinical presentations and associated features of TM perforation in adults in West Africa.
DESIGN: A prospective study.
SETTING: Tertiary referral centre, University hospital. PATIENTS OR OTHER PARTICIPANTS: Thirty-five (35) consecutive adults with TM perforations during a 1-year period had clinical evaluation of each TM using head mirror, video otoscopy, and micro-otoscopy. MAIN OUTCOME MEASURES: Clinical presentations and associated features of TM perforations.
RESULTS: Thirty-five patients, 20 (57%) men and 15 (43%) women, with 42 perforated TMs were examined. Twenty-eight (80%) patients had unilateral perforations. Infection was responsible for 90.5% of cases, and trauma was responsible for the rest. Locations of perforations were central (29; 69.1%), anteroinferior (4; 9.5%), posteroinferior (4; 9.5%), anterosuperior (3; 7.1%), and posterosuperior (2; 4.8%). The sizes of the perforations ranged from 1.2 to 83.2%. Large sizes of 25% and more were found to occur in humid and wet seasons, and also, clinical presentations of otorrhea (65.6%), otalgia (51.5%), tinnitus (37.1%), and ear itching (34.4%) seemed to worsen.
CONCLUSION: Most TM perforations result from infection and are preventable via appropriate health education. Posterosuperior perforation is rare, and this is probably one of the factors making choleasteatoma uncommon in West Africa. Approximately 83.3% of TM perforations measure more than 25% in size and appear during the wet humid season of the year. These findings are important for both local and foreign otolaryngologists who may be practicing in this subregion of the world.

Entities:  

Mesh:

Year:  2007        PMID: 17414040     DOI: 10.1097/MAO.0b013e3180311605

Source DB:  PubMed          Journal:  Otol Neurotol        ISSN: 1531-7129            Impact factor:   2.311


  8 in total

1.  Traumatic Tympanic Membrane Perforations Diagnosed in Emergency Departments.

Authors:  Eric T Carniol; Amishav Bresler; Kevin Shaigany; Peter Svider; Soly Baredes; Jean Anderson Eloy; Yu-Lan Mary Ying
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-02-01       Impact factor: 6.223

2.  The impact of topical and systemic enoxaparin sodium use on traumatic tympanic membrane perforation and myringosclerosis.

Authors:  Arif Bilge; Akif Gunes; Muharrem Dagli; F Fulya Koybasioglu; Ali Guvey
Journal:  Eur Arch Otorhinolaryngol       Date:  2016-01-21       Impact factor: 2.503

3.  Correlating the site of tympanic membrane perforation with Hearing loss.

Authors:  Titus S Ibekwe; Onyekwere G Nwaorgu; Taiwo G Ijaduola
Journal:  BMC Ear Nose Throat Disord       Date:  2009-01-04

4.  Conductive and Mixed Hearing Losses: A Comparison between Summer and Autumn.

Authors:  Mansoureh Nickbakht; Samira Borzoo
Journal:  Korean J Audiol       Date:  2014-04-14

Review 5.  Otitis media with effusion in Africa-prevalence and associated factors: A systematic review and meta-analysis.

Authors:  Emmanuel Choffor-Nchinda; Antoine Bola Siafa; Jobert Richie Nansseu
Journal:  Laryngoscope Investig Otolaryngol       Date:  2020-11-17

6.  Frequency Dependence Hearing Loss Evaluation in Perforated Tympanic Membrane.

Authors:  Mohammed Radef Dawood
Journal:  Int Arch Otorhinolaryngol       Date:  2017-02-28

7.  The anatomic determinants of conductive hearing loss secondary to tympanic membrane perforation.

Authors:  David J Carpenter; Debara L Tucci; David M Kaylie; Dennis O Frank-Ito
Journal:  J Otol       Date:  2017-06-29

8.  Effect of combination therapy with ceftizoxime and clotrimazole in the treatment of otomycosis.

Authors:  Saeid Mahdavi Omran; Zahra Yousefzade; Soraya Khafri; Mojtaba Taghizadeh-Armaki; Keyvan Kiakojuri
Journal:  Curr Med Mycol       Date:  2018-03
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.